These results lend additional support to the conclusion that EGFR806-CAR T cells have lower on-target, off-tumor activity than nonselective Erbitux-CAR T cells, as indicated by their minimal activation in wild type EGFR-expressing teratoma compared to Erbitux-CAR T cells. The gene discussed is EGFR; the disease is teratoma.